EU Referendum: EFPIA, Witty And Soriot Show Their Hands
This article was originally published in Scrip
Pharmaceutical industry associations have until recently remained pretty quiet over the prospect of a British exit from the EU. But following the announcement that the referendum will be held on June 23, that seems to be changing.
You may also be interested in...
With the UK about to go to the polls in a once-and-for-all decision on EU membership, the stakes for the life sciences sector are high. The effects of a Brexit would be far-reaching, not only for the industry but also for other key groups such as regulators, patients and researchers.
The Association of the British Pharmaceutical Industry has formally come out in support of the UK remaining part of the EU, saying that a vote to leave in next month's referendum would lead to delays in the availability of new drugs, have a detrimental effect on collaboration in European drug research, and discourage inward investment by international drug firms.
With the number of COVID-19 cases continuing to rise across Europe, the European Commission executive has published a set of actions to be taken at EU and national level to ensure future vaccines are allocated fairly, targeted at priority populations, and labeled in a way that increases production capacity, reduces transport costs and improves distribution.